VIB spin-off MRM Health receives approval for phase 2 clinical trial in pouchitis

VIB spin-off MRM Health, founded in 2020, has received approval from the Federal Agency for Health and Medicinal Products (FAGG) to start a Phase 2 clinical trial involving their novel therapeutic MH002 for the treatment of pouchitis in ulcerative colitis patients.

In patients with severe ulcerative colitis, a last resort option to alleviate symptoms is to perform a colectomy and to replace the removed parts of the bowel with a surgically reconstructed pouch. This so-called pouch allows patients to function normally without needing a stoma. Unfortunately, up to 50% of patients with a pouch suffer from pouchitis within the first 1 to 2 years after surgery. Disease mechanisms include impaired gut wall barrier function linked to gut microbiome dysbiosis, translocation of microbial products and resulting immune cell activation, leading to chronic inflammation in the gut wall.

MH002 consists of 6 well-characterized commensal strains that are optimized to form a synergistic micro-ecosystem driving differentiated potency, resiliency, and engraftment. Combining rational selection of disease-modifying strains with consortium optimization to ensure live delivery, engraftment, and durability is expected to result in greater efficacy than conventional microbiome therapeutics.

MRM Health’s Phase 2 study in pouchitis is a multi-center, open label trial which will enroll up to 20 acute pouchitis patients. The trial is designed to evaluate safety, mechanistic effects, and efficacy of MH002 on disease activity.


Lies Vanneste

Lies Vanneste

Investor Relations Manager, VIB

Share

Latest stories

Website preview
Spectacular Breakthrough in Sepsis Research: Vitamin B1 Stops Deadly Lactate Production and Opens the Door to a New Treatment
Ghent, July 29, 2025 – Scientists in Ghent have achieved a major breakthrough in sepsis research. In a study on mice, the researchers demonstrate that vitamin B1 (thiamine pyrophosphate, TPP) restores mitochondrial energy metabolism, drastically reduces lactate production, and increases survival rates in sepsis. The study results were published in Cell Reports.
press.vib.be
Website preview
Scientists discover brain switch that controls freeze-or-flight survival instincts
Leuven, Belgium, 23 July 2025 – Researchers have identified a key neural switch that controls whether animals instinctively flee from a threat or freeze in place. By comparing two closely related deer-mouse species, they found that this switch is calibrated by evolution to match the animal's habitat. This neural circuit is hypersensitive in mice living in densely vegetated environments, causing instant escape, but less responsive in their open-field cousins, who are more likely to freeze. In doing so, the research team uncovered an important way in which evolution fine-tunes the brain for survival.
press.vib.be
Website preview
Groundbreaking Study Offers a Novel Approach to Enhance Neuromuscular Function in Patients with Duchenne Muscular Dystrophy
Findings published in The American Journal of Pathology identify GLUD1 enzyme as a potential therapeutic target for muscle restoration through metabolic reprogramming, addressing clinically unmet need for treatment beyond symptom relief
press.vib.be

About VIB

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be